Vincenzo Dadduzio

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng et al. · Journal of Clinical Oncology · 2018 · 97 citations

Pathology, Prior Sorafenib, Pharmacotherapy +18

Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

Robin Kate Kelley, Tim Meyer, Lorenza Rimassa et al. · Clinical Cancer Research · 2020 · 82 citations · Full text

Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center

Camillo Aliberti, Riccardo Carandina, Sara Lonardi et al. · Journal of Vascular and Interventional Radiology · 2017 · 51 citations

Surgical Oncology, Small Drug-eluting Beads, Hepatology +12

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition

Lorenza Rimassa, Silvia Bozzarelli, Filippo Pietrantonio et al. · Clinical Colorectal Cancer · 2019 · 51 citations

Oncology, Acquired Resistance, Medicine +7

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo et al. · Liver Cancer · 2021 · 48 citations · Full text